NCT00651612已完成3 期
Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 604
- 主要终点
- Adverse Events
研究概览
简要总结
This study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of ocular hypertension or glaucoma
- •Patient requires IOP-lowering therapy in both eyes
排除标准
- •Uncontrolled medical conditions
- •Contraindication to β-adrenoceptor antagonist therapy or brimonidine therapy
研究组 & 干预措施
1
Experimental
Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
干预措施: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution (Drug)
2
Active Comparator
Concurrent Brimonidine 0.2% and 0.5% Timolol
干预措施: Concurrent brimonidine 0.2% and 0.5% timolol (Drug)
结局指标
主要结局
Adverse Events
时间窗: Day 10
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00652106Allergan432
已完成
3 期
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionOcular HypertensionNCT00332436Allergan586
已完成
2 期
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionOcular HypertensionNCT00332345Allergan73
已完成
3 期
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionOcular HypertensionNCT00332384Allergan573
已完成
3 期
Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00168363Allergan207